-
Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)
Thursday, February 27, 2014 - 1:26pm | 788Read More...Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...
-
Seven Stocks Insiders Are Buying
Friday, December 2, 2011 - 3:12pm | 792Read More...Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...
-
Jefferies Maintains Buy on Incyte
Tuesday, May 31, 2011 - 7:14am | 84Read More...Jefferies is out with its report today on Incyte (NASDAQ: INCY), maintaining Buy. In a note to clients, Jefferies writes, "While there were no major presentations for INCY's INCB28050 at EULAR, we note positive feedback from rheumatologists and new incremental details from the ORAL Solo Phase 3...
-
UPDATE: Oppenheimer Raises PT on Incyte to $25 (INCY)
Thursday, May 19, 2011 - 7:58am | 162Read More...Oppenheimer is out with its report today on Incyte (NASDAQ: INCY), raising its PT from $25 to $23. In a note to clients, Oppenheimer writes, "We conducted a survey of 25 practicing oncologists regarding INCB18424's potential in myelofibrosis and polycythemia vera. The survey results support our...
